FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Fluid/function correlation using AI-based quantification versus central subfield thickness in treatment-naïve and pre-treated patients with neovascular AMD in a real-world setting. PMID 40965041 · Acta Ophthalmol · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. PMID 40953785 · Clin Gastroenterol Hepatol · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Effect of Cognitive Behavioral Therapy-Based Psychoeducation on Anger Management and Death Anxiety in Individuals Receiving Chemotherapy: A Randomized Controlled Trial. PMID 38517134 · Omega (Westport) · 2026-May The study is a randomized trial in oncology patients, but it evaluates a psychoeducational intervention (CBT-based), not a drug. It also does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial. PMID 41976959 · J Clin Med · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial. PMID 41916997 · Nat Commun · 2026-Mar-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| RETRACTION: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). PMID 41916660 · BMJ · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| CORRECTION: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). PMID 41916658 · BMJ · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis. PMID 41915602 · Am J Nephrol · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Development of the Healthy Women Intervention to Increase Women's Engagement in Medication Treatment for Opioid Use Disorder: Mixed Methods, User-Centered Design Approach. PMID 41915447 · JMIR Form Res · 2026-Mar-31 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Perineal versus retropubic radical prostatectomy in localized prostate cancer: extended analysis of a prospective randomized cohort. PMID 41914230 · Arch Ital Urol Androl · 2026-Mar-31 The study is an oncology, human, randomized, original result report with a time-to-event endpoint (BCRFS). However, it does not involve a drug-containing intervention (it compares surgical techniques) and the phase of the trial is not specified as Phase III/IIIb or Phase II/III. Therefore, it is excluded based on the lack of a drug intervention and definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Aspirin in Colorectal Cancer Care: Who to Treat, When, and Why. PMID 41912748 · Curr Oncol Rep · 2026-Mar-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and Immunogenicity of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase III, Randomized, Blinded, Positive-Control Clinical Trial in Infants Aged Two Months. PMID 42042788 · Vaccines (Basel) · 2026-Mar-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. PMID 42017875 · J Am Coll Cardiol · 2026-Mar-30 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape. PMID 41930282 · Ann Neurosci · 2026-Mar-30 The record is a systematic review of the clinical trial landscape for metformin repurposing in neurological disorders, not an original report of a randomized trial in oncology. It does not contain results from a specific Phase III/IIIb or Phase II/III trial with a drug-containing intervention and a time-to-event efficacy endpoint. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM. PMID 41916623 · BMJ Open · 2026-Mar-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country. PMID 41913302 · BMC Rheumatol · 2026-Mar-30 The study is a randomized, drug-intervention trial with original results, but it is not an oncology study; it is for rheumatoid arthritis. Therefore, it does not meet the oncology requirement for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial. PMID 41912532 · NPJ Vaccines · 2026-Mar-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial. PMID 41911893 · J Natl Compr Canc Netw · 2026-Mar-30 The study is a randomized trial in cancer survivors but fails two key eligibility criteria: (1) it evaluates a lifestyle/diet intervention, not a drug-containing intervention, and (2) its primary efficacy endpoint is weight loss (a continuous measure), not a time-to-event endpoint (like OS, PFS, DFS) analyzed via Kaplan-Meier or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Motor Imagery and Action Observation in Breast Cancer Survivors: Protocol for a Randomized Controlled Trial. PMID 41911468 · JMIR Res Protoc · 2026-Mar-30 This is a protocol for a randomized controlled trial evaluating a non-drug rehabilitation intervention (motor imagery/action observation) in breast cancer survivors. It lacks a drug intervention, a time-to-event endpoint, and any trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer. PMID 41910867 · Breast Cancer Res Treat · 2026-Mar-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. PMID 42075805 · Pharmaceuticals (Basel) · 2026-Mar-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. PMID 41910394 · N Engl J Med · 2026-Mar-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of concurrent chemotherapy dose on long-term survival in locally advanced nasopharyngeal carcinoma: a 10-year single-center study. PMID 41904463 · BMC Cancer · 2026-Mar-28 The record does not explicitly establish that this is a Phase III, Phase IIIb, or Phase II/III trial. All other eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result) are met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial. PMID 41904192 · Nat Commun · 2026-Mar-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. PMID 41763229 · Lancet · 2026-Mar-28 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Global landscape of yttrium-90 clinical trials: a systematic registry-based analysis. PMID 41896975 · Trials · 2026-Mar-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma. PMID 41896823 · BMC Cancer · 2026-Mar-27 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 Study. PMID 41891657 · J Investig Allergol Clin Immunol · 2026-Mar-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial. PMID 41888754 · BMC Cancer · 2026-Mar-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Study protocol for hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced gastric cancer after laparoscopic or robotic Gastrectomy with D2 lymphadenectomy: a phase III multicentre prospective randomized controlled clinical trial (HIPEC-09). PMID 41888710 · BMC Cancer · 2026-Mar-26 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study. PMID 41888707 · BMC Cancer · 2026-Mar-26 The record describes a randomized study of an exploratory biomarker (monocyte ratio) for predicting response to metastasis-directed therapy (SBRT) in prostate cancer. It is an oncology human randomized trial with original results, but it does not meet key eligibility criteria: 1) The intervention is not drug-containing (compares iADT alone vs. iADT+SBRT, where SBRT is radiation, not a drug); 2) The endpoint is biochemical response/progression, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.; 3) It is a subgroup/biomarker analysis, not a primary report of a Phase III/IIIb or II/III drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study. PMID 41888696 · BMC Cancer · 2026-Mar-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031). PMID 41888667 · J Neurodev Disord · 2026-Mar-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prospective randomised trial comparing thermal ablation With laparoscopic Adrenalectomy as an alternatiVE treatment for unilateral asymmetric primary aldosteronism: a protocol for the WAVE trial. PMID 41887640 · BMJ Open · 2026-Mar-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Associations between perceived neighborhood environment and physical activity among breast cancer patients engaged in a physical activity program concomitant to cancer treatment: cross-sectional and longitudinal analyses in the DISCO trial (DiscoSpace). PMID 41882725 · Int J Behav Nutr Phys Act · 2026-Mar-26 The report is an original result of a human Phase III RCT in oncology, but it is a secondary observational analysis (nested within a trial) with a non-drug intervention (physical activity) and non-time-to-event endpoints (physical activity, walking distance). It does not meet the criteria for inclusion as a primary or key secondary efficacy analysis with a time-to-event endpoint and a drug intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism. PMID 41610160 · Cardiovasc Res · 2026-Mar-26 未发现恶性肿瘤人群证据。 |
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. PMID 41397287 · Blood · 2026-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Executive Summary of the American Radium Society Appropriate Use Criteria for Selective Use of Pelvic Radiation Therapy in Locally Advanced Rectal Cancer: A Consensus Statement. PMID 41895479 · Int J Radiat Oncol Biol Phys · 2026-Mar-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095. PMID 41882599 · BMC Cancer · 2026-Mar-25 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis. PMID 41882593 · BMC Cancer · 2026-Mar-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery. PMID 41882573 · BMC Cancer · 2026-Mar-25 This is a protocol for a randomized trial in colorectal cancer patients with a synbiotic intervention. It meets criteria for oncology, human, randomized, and drug intervention. However, it is excluded because it is a protocol without results, not explicitly a Phase III trial, and lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as the primary endpoint is quality of life. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study. PMID 41879928 · J Neurol · 2026-Mar-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study. PMID 41879875 · Pituitary · 2026-Mar-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study. PMID 39293971 · Circ J · 2026-Mar-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial. PMID 41877274 · Trials · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase. PMID 41876722 · Osteoporos Int · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Culturally Tailored Mobile Health Intervention to Improve Quality of Life in Black Survivors With Prostate Cancer: Protocol for a Stratified Randomized Controlled Trial. PMID 41875429 · JMIR Res Protoc · 2026-Mar-24 This is a protocol for a randomized controlled trial, not a final results report. The intervention is a mobile health app (non-drug) and standard care. The primary endpoint is quality of life (not a time-to-event endpoint). It lacks explicit phase information, but the description suggests an early-stage intervention trial, not a definitive Phase III study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners. PMID 41873569 · J Oncol Pharm Pract · 2026-Mar-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China. PMID 41872105 · Chin Med J (Engl) · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. PMID 41564431 · Blood Adv · 2026-Mar-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |